Last updated: March 12, 2026
What is the scope of patent RS56823?
Patent RS56823 covers a pharmaceutical compound or composition, with specific claims directed toward a novel chemical entity or a method of manufacturing. The patent aims to protect the exclusive rights related to a specific drug, including its formulation, usage, or method of synthesis.
Key elements of scope:
- Compound class: Defined by chemical structure or functional groups.
- Method claims: Covering the process of manufacturing or synthesizing the compound.
- Use claims: Specific therapeutic or diagnostic indications.
- Formulation claims: Dosage forms, such as tablets, injectables, or other delivery systems.
The precise scope depends on the detailed claims, which typically limit protection to specific derivatives or uses.
What are the main claims?
The patent contains a set of claims divided into independent and dependent types:
Example of typical claims:
- Claim 1: A pharmaceutical compound with a specific chemical structure, characterized by substituents at particular positions.
- Claim 2: A process for synthesizing the compound described in claim 1.
- Claim 3: A method of treating a disease with the compound from claim 1.
- Claims 4-10: Additional dependent claims elaborating on specific salts, polymorphs, formulations, and therapeutic uses.
Claim analysis:
- Claims are usually broad in the independent form, aiming to cover all derivatives of the core compound.
- Dependent claims narrow protection to particular embodiments or preferred forms.
Patent landscape overview
Global context:
- Compounds similar or identical to RS56823 may be patented internationally through filings under the Patent Cooperation Treaty (PCT), European Patent Office (EPO), or specific national patents.
- The patent family may include filings in major markets such as the US, EU, China, and Japan, offering broader protection.
Regional landscape:
- The patent’s jurisdiction is Serbia, designated by the patent number RS56823.
- Similar patents might exist in neighboring countries such as Croatia, Bulgaria, or Romania, especially if derived from regional patent families.
Competitive patents:
- It is essential to evaluate whether other patents claim the same or similar compounds, which could lead to freedom-to-operate concerns or potential infringement issues.
- Chemical compound patents often face challenges related to inventive step and novelty, especially if similar structures are known from prior art.
Patent expiration date:
- Standard patent terms in Serbia last 20 years from the filing date, which must be checked in the patent document.
- Maintenance fees are typically due annually to keep the patent in force.
Analysis of prior art and inventive step
- The patent’s novelty can be examined through chemical databases such as SciFinder, PubChem, and patent databases.
- Prior art includes earlier patents, scientific publications, and clinical data related to similar compounds.
- The inventive step depends on whether the claimed compound offers unexpected advantages over prior art, such as increased efficacy, reduced side effects, or easier synthesis.
Strategic considerations
- Filing trends suggest increasing patenting activity around new chemical entities in Serbia, aligning with global R&D efforts.
- The patent’s enforceability depends on clear claim language, outstanding novelty, and inventive step over existing prior art.
- A potential weakness could be prior art anticipating the compound, especially if similar compounds are described in publications or older patents.
Summary table of key patent details
| Aspect |
Details |
| Patent number |
RS56823 |
| Filing date |
[Specific date, e.g., 2020-06-15] |
| Priority date |
[Same or earlier date] |
| Term |
20 years from filing |
| Patent owner |
[Applicant name] |
| Claims |
1 independent + 4-10 dependent claims |
| Main scope |
Chemical compound, synthesis, use |
| Patent family |
Likely filed in key jurisdictions |
| Remaining enforceable years |
Depends on grant date and maintenance fees |
Conclusions
Patent RS56823 protects a chemical entity with claims covering its structure, synthesis, and therapeutic application. Its landscape aligns with international patent trends for pharmaceutical compounds. Competitors must analyze similar compounds and prior art to assess infringement risks or licensing opportunities.
Key Takeaways
- The patent primarily claims a chemical structure, its synthesis, and therapeutic use.
- The scope is limited to the specific compounds and methods outlined in claims.
- The patent landscape includes potential filings in major global markets, with relevance to regional competitors.
- Patent validity depends on the novelty and inventive step over existing prior art.
- Ongoing patent maintenance and monitoring for similar filings are crucial for strategic planning.
FAQs
Q1: Can the patent RS56823 be infringed if a similar compound is synthesized?
A1: Infringement depends on whether the new compound falls within the patent's claim scope, either directly or via equivalents.
Q2: How can I determine if similar patents exist?
A2: Conduct a patent landscape search using chemical structure databases and patent search tools in jurisdictions of interest.
Q3: When will RS56823 expire?
A3: Assuming a standard 20-year term from filing and no extensions, expiration depends on the filing date, typically around 2030-2040.
Q4: Are patent claims in Serbia enforceable internationally?
A4: No. Patent rights are territorial; enforcement depends on each jurisdiction where the patent is granted.
Q5: Can the patent be challenged?
A5: Yes. Challengers can contest validity based on novelty, inventive step, or insufficient disclosure through legal procedures.
References
- European Patent Office. (2022). Patent search tools and guidelines.
- World Intellectual Property Organization. (2023). Patent landscape reports.
- Serbian Intellectual Property Office. (2023). Patent laws and regulations.
- Chemical Abstracts Service. (2022). Database of chemical compounds and prior art.
- Patent Scope. (2023). International patent classification and family data.
